HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab SAMe review

This article was originally published in The Tan Sheet

Executive Summary

Only one of eight tested products contained inaccurate amounts of the ingredient compared with label claims, online testing firm announces. In a 2000 study, ConsumerLab.com found six of 13 tested products contained less SAMe (S-adenosyl-methionine) than labeled (1"The Tan Sheet" April 10, 2000, In Brief). The improvement in results was consistent to data collected from a study earlier this month finding an improvement in the labeling accuracy of chondroitin supplements (2"The Tan Sheet" Nov. 3, 2003, In Brief)...

You may also be interested in...



SAMe comes up short

Six of 13 supplement products tested contain less SAMe than labeled, ConsumerLab.com announces. SAMe results join those of glucosamine/chondroitin, ginkgo biloba and saw palmetto featured on the site and on eNutrition.com, which will halt sales of failed products. One-year licensing agreement makes the retailer the first to use the ConsumerLab.com Seal of Approved Quality. Recent University of Maryland study finds similar discrepancies for glucosamine/chondroitin products (1see item, p. 19). ConsumerLab.com will release a report on vitamin C in April

Darzalex Surpasses Stelara As J&J’s Best-Selling Drug

Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel